Q1 2023: Positive one-off effects contributed to growth
Important events during the first quarter · Net sales increased by 11% (2% adjusted for currency effects) to SEK 172 m (155). · The EBITDA margin amounted to 28% (25). · Positive one-off effects totaling SEK 18 m regarding postponed orders from Q4 2022. · Takeover of the distribution of our own brand Probi[®] in Sweden from April 1, 2023. New market organization established. · First commercial batch of spores produced. · Anita Johansen appointed CEO of Probi on March 30. Von Carlson took over as the new VP of Operations on March 27. CEO Comments A strengthened